Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pulmonary Arterial Hypertension
Open-data reference.
64 US clinical trials · 21 currently recruiting
Active & Recent Trials
Rutgers University Study of the Genetics of Pulmonary Hypertension
Rutgers, The State University of New Jersey
NCT07217522
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Duke University
NCT04278404
Pulmonary Hypertension Association Registry
Pulmonary Hypertension Association
NCT04071327
Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry
New York Medical College
NCT02249923
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
Merck Sharp & Dohme
NCT07218029
Pulmonary Hypertension Biorepository and Registry
University of Kansas Medical Center
NCT04808596
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
Vanderbilt University Medical Center
NCT05464095
PET Image in PAH Patients
Stephen Y. Chan
NCT05452889
Spironolactone for Pulmonary Arterial Hypertension
National Institutes of Health Clinical Center (CC)
NCT01712620
Xenon MRI Pulm Hypertension
Bastiaan Driehuys
NCT04991454
Repurposing Valsartan May Protect Against Pulmonary Hypertension
University of Washington
NCT06053580
Mobile Health Intervention to Improve Exercise in Pediatric PH
Vanderbilt University Medical Center
NCT06549452
A Study of Pulmonary Hypertension Peripheral Limitations
Mayo Clinic
NCT05968859
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
Merck Sharp & Dohme
NCT05587712
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
Aria CV
NCT04555161
Pulmonary Hypertension SOLAR
Bastiaan Driehuys
NCT04778046
A Placebo-controlled, Randomized Clinical Trial to Assess the Safety, Feasibility, and Pharmacokinetics of Microbiota Transplant Therapy With Antibiotic Preconditioning and Fiber Supplementation in Patients With Pulmonary Arterial Hypertension
University of Minnesota
NCT06481852
Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH
University of Arizona
NCT04062565
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
Bastiaan Driehuys
NCT06104228
Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)
V-Wave
NCT03838445
129 Xenon Imaging in Patients Treated With Sotatercept
Bastiaan Driehuys
NCT06351345
Pulmonary Vascular Disease Phenomics Program PVDOMICS
The Cleveland Clinic
NCT02980887
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
Actelion
NCT04273945
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
GB002
NCT06274801
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
United Therapeutics
NCT03045029
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)
Merck Sharp & Dohme
NCT06925750
A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension
Pfizer
NCT06137742
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
Insmed Incorporated
NCT05649748
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
GB002, Inc., a wholly owned subsidiary of Gossamer Bio
NCT04816604
DelIVery for Pulmonary Arterial Hypertension (PAH) & Continued Support Study
Medtronic Cardiac Rhythm and Heart Failure
NCT01321073
Utility of At-home Monitoring of Exercise Capacity by App-based 6-minute Walk Test
Stanford University
NCT03893500
A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension
Actelion
NCT03492177
A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
United Therapeutics
NCT05203510
Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE)
The Cleveland Clinic
NCT03288025
Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension
Mayo Clinic
NCT06409026
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
Liquidia Technologies
NCT04691154
Safety and Impact of Low Resistance Exercise Training on Quality of Life in Pulmonary Arterial Hypertension
University of Pennsylvania
NCT06543745
Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension
University of Kansas Medical Center
NCT05339386
The Effects of Drug Candidate CS1 on Lung Structure and Function Utilizing FRI
Prisma Health-Upstate
NCT06907693
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
United Therapeutics
NCT01266265
A Registry for Patients Taking Uptravi
Actelion
NCT03278002
The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
Actelion
NCT02558231
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)
Merck Sharp & Dohme
NCT06664801
Novel Screening Strategies for Scleroderma PAH
University of Michigan
NCT01959815
Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.
Actelion
NCT03078907
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
Pfizer's Upjohn has merged with Mylan to form Viatris
NCT00323297
Biomarkers in the Diagnosis and Assessment of Pulmonary Arterial Hypertension (PAH)
Northwell Health
NCT00566423
Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)
Gilead Sciences
NCT00617305
Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)
Lung Biotechnology PBC
NCT00989963
EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension
United Therapeutics
NCT03497689
Right Ventricular Metabolism in Pulmonary Arterial Hypertension
Vanderbilt University Medical Center
NCT02763735
Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension
University of Alabama at Birmingham
NCT01330108
Subcutaneous Elafin in Healthy Subjects
Roham T. Zamanian
NCT03522935
Effects of DHEA in Pulmonary Hypertension
Rhode Island Hospital
NCT03648385
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
Johns Hopkins University
NCT01042158
Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension
University of Cincinnati
NCT00403650
Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension
Actelion
NCT03187678
Anastrozole in Patients With Pulmonary Arterial Hypertension
University of Pennsylvania
NCT01545336
Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)
University of Chicago
NCT00452218
A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension
University of Chicago
NCT01757808
Nitric Oxide, GeNO Nitrosyl Delivery System
Wake Forest University Health Sciences
NCT01165047
Oral Iron Supplementation in Pulmonary Hypertension
The Cleveland Clinic
NCT01446848
Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
NCT01268553
Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401
Actelion
NCT01105117
Phase Distribution
| Phase | Trial count |
|---|---|
| Early Phase 1 | 6 |
| Phase 2 | 16 |
| Phase 3 | 7 |
| Phase 4 | 11 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Pulmonary Arterial Hypertension Trial Landscape
ClinicalTrials.gov lists 64 US studies indexed under Pulmonary Arterial Hypertension, and 21 of those are currently open to recruitment — roughly 33% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Pulmonary Arterial Hypertension shows 18 late-stage studies (Phase 3 and Phase 4 combined) alongside 22 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Pulmonary Arterial Hypertension is led by Actelion with 7 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 64 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Pulmonary Arterial Hypertension?
PlainTrial tracks 64 US clinical trials for Pulmonary Arterial Hypertension, of which 21 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Pulmonary Arterial Hypertension?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.